Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

Long-term outcomes and complications in cancer patients who have recovered from...

Dr David Pinato - Imperial College London, London, UK

Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )

Multidisciplinary management of ovarian germ cell tumours - a single...

Dr Sandip Ganguly - Tata Medical Center, Kolkata, India

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma...

Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Cannabis in cancer care and survivorship

Dr Ashwin Mehtha - Memorial Healthcare System, FL, USA

Cannabis in cancer care and survivorship ( Dr Ashwin Mehtha - Memorial Healthcare System, FL, USA )

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC...

Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and...

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The...

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )

More from ecancer